⟵ Back to Search Results

BGB-A317-A1217-302 AdvanTIG-302

Recruiting

A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer

Beigene Study ID info

BGB-A317-A1217-302 AdvanTIG-302

ClinicalTrials.gov ID info

NCT04746924

Study Overview

Sex: All

Age: 18 Years and older (Adult, Older Adult)

Accepts Healthy Volunteers? yes

No Study Documents

Locations

Study Overview

Sex: All

Age: 18 Years and older (Adult, Older Adult)

Accepts Healthy Volunteers? yes

No Study Documents